Cell and Gene Therapy Today—November 6, 2025
This week’s cell and gene therapy update spotlights key developments,…
Lucid Diligence Brief: AAVantgarde Bio $141M Series B
Lucid Diligence Brief: AAVantgarde Bio $141M Series B Professional audiences…
Lucid Diligence Brief: Lilly to acquire Adverum Biotechnologies
Lucid Diligence Brief: Lilly to acquire Adverum Biotechnologies Professional…
EURETINA 2025 Preview: Key Retinal Disease Highlights to Watch
EURETINA 2025 at a glance Looking ahead to EURETINA 2025, LucidQuest outlines…
Cell and Gene Therapy Weekly News - May 29th 2025
This Week in Gene & Cell Therapy: Clinical Trial Expansions, Rare Disease…
ASGCT 2025 PREVIEW: Key Cell and Gene Therapy Highlights to Watch
ASGCT 2025 at a glance Count down to ASGCT 2025 with LucidQuest’s brief…
Gene therapy treatments for Inherited Retinal Disorders (IRD) hold great promise.
Globally 4.5 million people are affected by IRDs — a group of diseases having a…